Fmr LLC Grows Stock Position in Arcellx, Inc. (NASDAQ:ACLX)

FMR LLC boosted its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 22.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,956,633 shares of the company's stock after purchasing an additional 1,477,360 shares during the period. FMR LLC owned about 14.71% of Arcellx worth $610,194,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Arcellx by 35.3% during the fourth quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company's stock valued at $255,385,000 after purchasing an additional 867,996 shares in the last quarter. Geode Capital Management LLC increased its holdings in Arcellx by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 979,026 shares of the company's stock worth $75,098,000 after acquiring an additional 4,059 shares in the last quarter. Lord Abbett & CO. LLC lifted its holdings in Arcellx by 2.1% during the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock valued at $74,478,000 after purchasing an additional 18,004 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Arcellx by 4.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 343,085 shares of the company's stock worth $26,311,000 after purchasing an additional 14,992 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Arcellx by 141.4% during the 4th quarter. Federated Hermes Inc. now owns 156,094 shares of the company's stock valued at $11,971,000 after purchasing an additional 91,430 shares during the period. 96.03% of the stock is currently owned by institutional investors.

Arcellx Trading Up 1.4 %

Shares of ACLX traded up $0.83 during trading hours on Monday, reaching $59.98. 78,478 shares of the stock traded hands, compared to its average volume of 555,420. The company's 50-day moving average price is $65.44 and its two-hundred day moving average price is $75.90. The company has a market cap of $3.30 billion, a P/E ratio of -84.48 and a beta of 0.33. Arcellx, Inc. has a 52-week low of $47.88 and a 52-week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The business had revenue of $15.27 million during the quarter, compared to analysts' expectations of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. On average, research analysts forecast that Arcellx, Inc. will post -1.58 EPS for the current year.

Insider Activity at Arcellx

In related news, insider Rami Elghandour sold 38,300 shares of the company's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the sale, the insider now owns 149,186 shares of the company's stock, valued at $9,252,515.72. This represents a 20.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $71.64, for a total transaction of $107,460.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,955 shares of company stock valued at $3,507,263. Corporate insiders own 6.24% of the company's stock.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).